Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease

Mycobacterium Avium Clinical Trial

Official title:

The Pathogenic Role and Diagnostic Implication of Program Cell Death Receptor 1 Expressed on T Cells in Mycobacterium Avium Complex Lung Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02779049
• Other study ID #: 201407079RIND
• Status: Completed
• Phase: N/A
• First received: May 18, 2016
• Last updated: December 13, 2016
• Start date: January 2015
• Est. completion date: July 2016

Study information

• Verified date: December 2016
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Ministry of Health and Welfare
• Study type: Observational

Clinical Trial Summary

1. To understand the components of PBMC in MAC-LD patients, including T cells, B cells, nature killer cells, and monocyte.

2. To confirm the phenomenon of reduced PBMC response in MAC-LD patients

3. To study the proportion of apoptosis and PD-1 expression in T cells among MAC-LD patients, MAC colonizers, patients with tuberculosis, and healthy controls.

4. To study the apoptosis and PD-1/PD-L1 expression in T cells/macrophage from bronchial lavage among MAC-LD patients, MAC colonizers, patients with tuberculosis,

5. To examine the PD-1 gene polymorphism and the correlation with MAC-LD.

Description:

Background: Nontuberculous mycobacteria Lung disease (NTM-LD) becomes an important clinical concern, because its incidence has increased over the last decade. Mycobacterium avium complex (MAC) is the most common responsible species for NTM-LD in Taiwan. The clinical relevance of MAC in sputum is, however, only 35~42% because it exists in the environment ubiquitously. According to the guideline of the American Thoracic Society, the diagnosis of MAC-LD is based on clinical, radiographic, and mycobacteriology criteria which require two or more positive sputum cultures for MAC. The major limitation of mycobacterial culture is the long turn-around-time, usually 2-4 weeks. In addition, both mycobacterial culture and nucleic acid amplification test cannot discriminate true MAC infection and colonization because airway colonization of MAC is not uncommon. Therefore, diagnosis of MAC-LD remains a big challenge in clinical practice, and rapid and accurate diagnostic test should be developed.

Beyond the contemporary diagnostic criteria, the host immune response in NTM disease has recently been proposed to help diagnosis. Inflammatory markers may represent host response and discriminate MAC infection from colonization. But inflammatory markers can be influenced by infection other than MAC infection. By contrast, lymphocyte response to antigen stimulation may be more specific in diagnosis. In our preliminary results, in-vitro response of peripheral blood mononuclear cell (PBMC) is lower in MAC-LD than healthy controls. The underlying mechanism responsible for the reduced PBMC response in MAC-LD is not fully understood. In previous studies conducted in tuberculosis patients, interaction between programmed cell death ligand-1 (PD-L1) from dendritic cells and programmed cell death-1 (PD-1) in T cells leads to apoptosis or anergy of T lymphocyte and thus suppresses cellular immunity. Therefore, it is possible that similar alteration in immune response also occurs in patients with MAC-LD and correlates with the PBMC response as well as disease severity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Age = 20 years

• MAC lung disease: Diagnosis is based on the guidelines by American Thoracic Society. In brief, there should be pulmonary symptoms, comparable findings in chest image and appropriate exclusion other possible causes as well as meeting the microbiology criteria.

• MAC pulmonary colonizers: Those without fulfilling the diagnostic criteria but having at least one set of positive sputum for MAC are defined.

• Healthy controls:

• Active tuberculosis group: patients with pulmonary tuberculosis diagnosed by positive respiratory culture

Exclusion Criteria:

• Patients who have acquired immunodeficiency syndrome

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lung Diseases
• Mycobacterium Avium
• Mycobacterium avium-intracellulare Infection
• Mycobacterium Infections

Intervention

Other:
• Blood examination
blood sampling

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent of disease progression		2 year	No